Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.39 |
| ▸ | NAMPT | P43490 | 5/20 | 0.39 |
| ▸ | PRMT3 | O60678 | 2/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.37 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.37 |
| ▸ | PREP | P48147 | 1/20 | 0.37 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10135691 | 0.98 | CYP2C9 (0.43) | CYP2C9GPR119NAMPTPRMT3DYRK1A | |
| SCHEMBL10135650 | 0.92 | CYP2C9 (0.44) | CYP2C9GPR119NAMPTPRMT3PRMT5 | |
| SCHEMBL10135623 | 0.88 | GPR119 (0.47) | CYP2C9GPR119NAMPTPRMT3 | |
| SCHEMBL10135633 | 0.88 | GPR119 (0.47) | CYP2C9GPR119NAMPTPRMT3 | |
| SCHEMBL10135673 | 0.86 | GPR119 (0.47) | CYP2C9GPR119NAMPTPRMT3PREP | |
| SCHEMBL10135696 | 0.85 | GPR119 (0.46) | CYP2C9GPR119NAMPTPRMT3PREP | |
| SCHEMBL10135733 | 0.85 | GPR119 (0.46) | CYP2C9GPR119NAMPTPRMT3PREP | |
| SCHEMBL10135867 | 0.84 | CYP2C9 (0.45) | CYP2C9GPR119NAMPTPRMT3USP30 | |
| SCHEMBL10135789 | 0.84 | GPR119 (0.43) | CYP2C9GPR119NAMPTDYRK1A | |
| SCHEMBL10135769 | 0.84 | GPR119 (0.43) | CYP2C9GPR119NAMPTDYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8951997-B2 | Substituted isoquinoline derivative | D. WESTERN THERAPEUTICS INSTITUTE, INC. (JP) | 2015-02-10 | — | — | US | disclosed |
| US-20120035159-A1 | SUBSTITUTED ISOQUINOLINE DERIVATIVE | D. WESTERN THERAPEUTICS INSTITUTE, INC (JP) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035159-A1 | SUBSTITUTED ISOQUINOLINE DERIVATIVE | SULT1A1, SULT1E1, SULT2A1 | CYP2C9 1512/4885GPR119 2496/4885NAMPT 2732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.